These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24049176)

  • 1. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.
    Serre SB; Krarup HB; Bukh J; Gottwein JM
    J Virol; 2013 Dec; 87(23):12776-93. PubMed ID: 24049176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.
    Prentoe J; Serre SB; Ramirez S; Nicosia A; Gottwein JM; Bukh J
    J Virol; 2014 Feb; 88(3):1725-39. PubMed ID: 24257605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
    PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.
    Carlsen TH; Scheel TK; Ramirez S; Foung SK; Bukh J
    J Virol; 2013 Feb; 87(3):1385-99. PubMed ID: 23152512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.
    Scheel TK; Gottwein JM; Carlsen TH; Li YP; Jensen TB; Spengler U; Weis N; Bukh J
    J Virol; 2011 Mar; 85(6):2891-906. PubMed ID: 21177811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different susceptibilities of genetic variants of hepatitis C virus (HCV) to interferon (IFN).
    Lu M; Wiese M; Funsch B; Roggendorf M
    Arch Virol; 1997; 142(3):581-8. PubMed ID: 9349304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro.
    Kuga C; Enomoto H; Aizawa N; Takashima T; Ikeda N; Ishii A; Sakai Y; Iwata Y; Tanaka H; Saito M; Iijma H; Nishiguchi S
    Biochem Biophys Res Commun; 2014 Nov; 454(3):453-8. PubMed ID: 25450683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient infectious cell culture systems of the hepatitis C virus (HCV) prototype strains HCV-1 and H77.
    Li YP; Ramirez S; Mikkelsen L; Bukh J
    J Virol; 2015 Jan; 89(1):811-23. PubMed ID: 25355880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.
    Gottwein JM; Scheel TK; Hoegh AM; Lademann JB; Eugen-Olsen J; Lisby G; Bukh J
    Gastroenterology; 2007 Nov; 133(5):1614-26. PubMed ID: 17983807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.
    Lee M; Yang J; Jo E; Lee JY; Kim HY; Bartenschlager R; Shin EC; Bae YS; Windisch MP
    Sci Rep; 2017 Mar; 7():44676. PubMed ID: 28333153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response.
    Bauhofer O; Ruggieri A; Schmid B; Schirmacher P; Bartenschlager R
    Gastroenterology; 2012 Aug; 143(2):429-38.e8. PubMed ID: 22522091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.
    Hofmann WP; Zeuzem S; Sarrazin C
    J Clin Virol; 2005 Feb; 32(2):86-91. PubMed ID: 15653410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
    Hoffmann L; Ramos JA; Souza EV; Araújo Ramos AL; Villela-Nogueira CA; Urményi TP; Tanuri A; Rondinelli E; Silva R
    Virol J; 2013 Feb; 10():57. PubMed ID: 23409973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
    Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
    Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.